PMID- 29440931
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 10
DP  - 2018
TI  - Influential factors on radiotherapy efficacy and prognosis in patients with 
      secondary lymph node metastasis after esophagectomy of thoracic esophageal 
      squamous cell carcinoma.
PG  - 217-225
LID - 10.2147/CMAR.S147324 [doi]
AB  - BACKGROUND: The purpose of this study was to clarify whether pretreatment tumor 
      burden-related index, including the gross tumor volume (GTV) of metastatic lymph 
      nodes (V(LN)) and maximum diameter of metastatic lymph nodes (D(LN)), and 
      inflammatory markers, consisting of neutrophil-to-lymphocyte ratio (NLR) and 
      platelet-to-lymphocyte ratio (PLR), are useful for assessing the therapeutic 
      effects and prognosis with secondary lymph node metastasis (LNM) receiving 
      chemoradiotherapy (CRT) or radiotherapy (RT) alone after resection of esophageal 
      squamous cell carcinoma (ESCC). PATIENTS AND METHODS: A total of 119 patients 
      with secondary LNM after resection of ESCC were recruited and received curative 
      RT only or CRT. The enrolled patients were grouped according to the median values 
      of NLR, PLR, V(LN), and D(LN). The relationship between the responsiveness to 
      treatment and these markers was analyzed by logistic analysis. The Kaplan-Meier 
      method and log-rank test were adopted to calculate and compare the overall 
      survival (OS) rates with these markers. The Cox models were used to carry out 
      multivariate analyses. RESULTS: Univariate logistic regression analysis showed 
      that the responses to treatment were highly associated with treatment method 
      (P=0.011), NLR (P=0.000), PLR (P=0.003), V(LN) (P=0.000), and D(LN) (P=0.000). 
      Next, multivariate logistic regression analysis showed that therapeutic method 
      (hazard ratio [HR]=1.225, P=0.032), NLR (HR=2.697, P=0.019), and V(LN) (HR=4.607, 
      P=0.034) were independent risk factors for tumor response. Additionally, 
      Kaplan-Meier survival analysis of this cohort revealed that NLR (chi(2) =27.298, 
      P=0.000), PLR (chi(2)=16.719, P=0.000), V(LN) (chi(2)=48.823, P=0.000), D(LN) 
      (chi(2)=40.724, P=0.000), and treatment methods (chi(2)=18.454, P=0.018) were 
      significantly associated with OS. Furthermore, multivariate analysis was 
      performed, and the results showed that therapeutic method (HR=1.223, P=0.048), 
      NLR (HR=2.000, P=0.018), V(LN) (HR=2.379, P=0.020), and D(LN) (HR=2.901, P=0.002) 
      were considered independent prognostic factors for OS. CONCLUSION: This study 
      found that NLR and V(LN) were promising as predictive markers for therapeutic 
      effects, and NLR combined with V(LN) and with D(LN) might be useful biomarkers in 
      predicting outcomes in patients with secondary LNM receiving CRT or single RT 
      after esophagectomy.
FAU - Zhou, Shao-Bing
AU  - Zhou SB
AD  - Department of Radiation Oncology, Affiliated Taixing People's Hospital of 
      Yangzhou University, Taixing.
FAU - Guo, Xin-Wei
AU  - Guo XW
AD  - Department of Radiation Oncology, Affiliated Taixing People's Hospital of 
      Yangzhou University, Taixing.
FAU - Gu, Liang
AU  - Gu L
AD  - Department of Radiation Oncology, Affiliated Taixing People's Hospital of 
      Yangzhou University, Taixing.
FAU - Ji, Sheng-Jun
AU  - Ji SJ
AD  - Department of Radiotherapy and Oncology, Nanjing Medical University Affiliated 
      Suzhou Hospital, Suzhou, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20180202
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC5798555
OTO - NOTNLM
OT  - chemoradiotherapy
OT  - esophageal carcinoma
OT  - hematological markers
OT  - prognostic factor
OT  - therapeutic response
OT  - tumor volume
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/02/15 06:00
MHDA- 2018/02/15 06:01
PMCR- 2018/02/02
CRDT- 2018/02/15 06:00
PHST- 2018/02/15 06:00 [entrez]
PHST- 2018/02/15 06:00 [pubmed]
PHST- 2018/02/15 06:01 [medline]
PHST- 2018/02/02 00:00 [pmc-release]
AID - cmar-10-217 [pii]
AID - 10.2147/CMAR.S147324 [doi]
PST - epublish
SO  - Cancer Manag Res. 2018 Feb 2;10:217-225. doi: 10.2147/CMAR.S147324. eCollection 
      2018.